Email this article 
Post a Comment Effectiveness and safety of combination antiretroviral therapy schemes for acute HIV infection
- Authors: Ivanova E.S.1, Sheludko V.S.2, Vorobjeva N.N.2, Okishev M.A.2, Nikolenko V.V.2, Sumlivaya O.N.2, Semerikov V.V.3, Teterin V.Y.2
-
Affiliations:
- Perm Regional Center for Prevention and Control of AIDS and Infectious Diseases
- Ye.A. Vagner Perm State Medical University
- Perm Regional Clinical Infectious Diseases Hospital
- Issue: Vol 42, No 5 (2025)
- Pages: 58-65
- Section: Original studies
- URL: https://bakhtiniada.ru/PMJ/article/view/351531
- DOI: https://doi.org/10.17816/pmj42558-65
- ID: 351531
Cite item
Full Text
Abstract
Objective. To conduct a comparative study of efficacy and safety of treatment with nucleoside reverse transcriptase inhibitors (NRTIs) – phosphazide and tenofovir in patients with acute HIV infection.
Materials and methods. A comparative study to evaluate the efficacy and safety of domestic drugs phosphazide and tenofovir in combination antiretroviral therapy regimens for acute HIV infection was conducted for 48 weeks in Perm Regional Center for AIDS and Infectious Diseases in 2017-2019. A total of 28 patients, divided into 2 groups, were included into the study. All patients underwent early diagnosis of HIV infection using enzyme immunoassay, immunoblotting, detection of HIV DNA and RNA by polymerase chain reaction (PCR); indicators of cellular immunity were determined – the level of CD4 + lymphocytes, assessment of clinical status before the start of the prescribed combination antiretroviral treatment and after 2, 4, 12, 24, 36 and 48 weeks.
Results. High virological, immunological, clinical efficacy and safety of the use of antiretroviral therapy (ART) regimens containing phosphazide or tenofovir in combination with lamivudine and efavirenz in the treatment of the acute stage of HIV infection have been demonstrated. These drugs can be recommended for use in the first-line therapy.
Conclusions. The conducted study allows us to recommend the scheme of using phosphazide in combination with lamivudine and efavirenz for the first-line therapy in HIV-infected patients. Further optimization of antiretroviral therapy of HIV infection based on phosphazide involves creation of a combination of fixed doses with a frequency of use once a day for the treatment of HIV/AIDS as new dosage forms.
Full Text
##article.viewOnOriginalSite##About the authors
E. S. Ivanova
Perm Regional Center for Prevention and Control of AIDS and Infectious Diseases
Email: okishev_mikhail@mail.ru
ORCID iD: 0000-0001-8756-9854
PhD (Medicine), Head of the Department of Medical Care
Russian Federation, PermV. S. Sheludko
Ye.A. Vagner Perm State Medical University
Email: okishev_mikhail@mail.ru
ORCID iD: 0000-0002-7080-9142
PhD (Medicine), Specialist of the Department of Research Activities
Russian Federation, PermN. N. Vorobjeva
Ye.A. Vagner Perm State Medical University
Email: okishev_mikhail@mail.ru
ORCID iD: 0000-0001-5384-5910
DSc (Medicine), Professor, Head of the Department of Infectious Diseases
Russian Federation, PermM. A. Okishev
Ye.A. Vagner Perm State Medical University
Author for correspondence.
Email: okishev_mikhail@mail.ru
ORCID iD: 0000-0002-9461-7145
PhD (Medicine), Associate Professor of the Department of Infectious Diseases
Russian Federation, PermV. V. Nikolenko
Ye.A. Vagner Perm State Medical University
Email: okishev_mikhail@mail.ru
DSc (Medicine), Professor of the Department of Infectious Diseases
Russian Federation, PermO. N. Sumlivaya
Ye.A. Vagner Perm State Medical University
Email: okishev_mikhail@mail.ru
ORCID iD: 0000-0003-0498-4900
DSc (Medicine), Professor of the Department of Infectious Diseases
Russian Federation, PermV. V. Semerikov
Perm Regional Clinical Infectious Diseases Hospital
Email: okishev_mikhail@mail.ru
ORCID iD: 0000-0002-5346-8104
DSc (Medicine), Head of the Department of Epidemiology
Russian Federation, PermV. Yu. Teterin
Ye.A. Vagner Perm State Medical University
Email: okishev_mikhail@mail.ru
ORCID iD: 0009-0007-2162-8111
PhD (Medicine), Associate Professor of the Department of Infectious Diseases
Russian Federation, PermReferences
- Кравченко А.В., Орлова-Морозова Е.А., Шимонова Т.Е., Козырев О.А., Нагимова Ф.Я., Захарова Н.Г., Иванова Э.С., Куимова У.А., Ефремова О.А., Сонин Д.Б., Чернова О.Э., Тонких О.С., Яковлев А.А., Курина Н.В., Покровский В.В., Бычко В.В., Востокова Н.В., Зозуля О.В. Эффективность и безопасность нового российского ненуклеозидного ингибитора обратной транскриптазы элсульфавирина в сочетании с тенофовиром/эмтрицитабином – многоцентровое сравнительное исследование с эфавирензом у пациентов с ВИЧ-инфекцией, ранее не получавших лечение. Инфекционные болезни 2017; 15 (3): 3–11. doi: 10.20953/1729-9225-2017-3-5-13 / Kravchenko A.V. Orlova-Morozova E.A. SHimonova T.E. Kozyrev O.A. Nagimova F. IA. Zakharova N.G. Ivanova E.S. Kuimova U.A. Efremova O.A. Sonin D.B. CHernova O.E. Tonkikh O.S. IAkovlev A.A. Kurina N.V. Pokrovskii V.V. Bychko V.V. Vostokova N.V. Zozulia O.V. Efficacy and safety of the new Russian non-nucleoside reverse transcriptase inhibitor elsulfavirin in combination with tenofovir/emtricitabine – a multicenter comparative study with efavirenz in treatment-naïve patients with HIV infection. Infectious diseases 2017; 15 (3): 3–11. doi: 10.20953/1729-9225-2017-3-5-13 (in Russian).
- Martin Hoenigl, Susan J. Little How can we detect HIV during the acute or primary stage of infection? Expert Rev Mol Diagn 2016; 16 (10): 1049–1051. doi: 10.1080/14737159.2016.1226805
- Филиппов П.Г., Огиенко О.Л., Тишкевич О.А. Острая ВИЧ-инфекция и гиперактивация иммунной системы: клинический случай развития гемофагоцитарного синдрома. Инфекционные болезни 2021; 10 (1): 98–104. doi: 10.33029/2305-3496-2021-10-1-98-104 / Filippov P.G. Ogienko O.L. Tishkevich O.A. Acute HIV infection and hyperactivation of the immune system: a clinical case of the development of hemophagocytic syndrome. Infectious diseases 2021; 10 (1): 98–104. doi: 10.33029/2305-3496-2021-10-1-98-104 (in Russian).
- Khoury G., Framentin R., Solomon A. Human immunodeficiency virus persistence and t-cell activation in blood, recial, and lymph node tissue in human immunodeficiency virus-infected individuals receiving suppressive antiretroviral therapy. J Infect Dis 2017; 215: 911–919. doi: 10.1093/infdis/jix039
- Cjlby D.J., Trautmann L., Pinyakom S. Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection Nat Med 2018; 24 (7): 924–926. doi: 10.1038/b41591-018-0026-6.
- Richard M. Selik, Laurie Lindey. Viral loads within 6 weeks after diagnosis of HIV infection in early and later stages: observational study using national surveillance data. Division of HIV/AIDS and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention. Atlanta, GA, United States. doi: 10.2196/10770
- De Paula H.H.S., Ferreira F.G.G., Caetano D.G., Delatorre E., Teixeira S.L.M., Coelho L.E., Joao E.G., de Andrade M.M., Cardoso S.W., Grinsztejn B., Veloso V.G., Morgado M.G., Guimaraes M.L., Cortes F.H. Reduction of inflammation and T cell activation after 6 months of cART initiation during acute, but not early chronic HIV-1 infection. Retrovirology 2018; 15: 76. doi: 10.1186/s12977-018-0458-6
- Toussova J.V., Kozlov A.P., Verevochkin S.V., Lancaster K.E., Shaboltas A.V., Masharsky A., Dukhovlinova E., Miller W.C., Hoffman I.F. A Cohort approach to real-time detection of acute HIV infections among people who inject drugs in St. Petersburg, Russia. Aids Research and Human Retroviruses 2018; 34 (3): 261–268. doi: 10.1089/aid.2017.0076
- Manak V.V., Eller L.A., Valia J., Jagodzinski L.L., Trichavaroj R., Oundo J., Lueer C., Cham F., de Souza M., Nichael N.L., Robb V.L., Peel S.A. Identification of acute HIV-1 infection by hologic aptima HIV-1 RNA qualitative assay. Journal of Clinical Microbiology 2017; 55 (7): 2064–2073. PMID: 28424253. PMCID: PMC5483908. doi: 10.1128/JCM.00431-17
- Gu W.M., Hu Y., Hu W.Z., Xu B. Dynamic changes in biomarkers in acute human immunodeficiency virus infection: a case report. BMC Res Notes 2017; 10: 65. doi: 10.1186/s13104-017-2392-4
- Griffin D.O. The diagnosis of symptomatic acute antiretroviral syndrome during the window period with antigen/antibody testing and HIV viral load. Idcases 2018; 12: 157–160. doi: 10.1016/j.idcr.2018.05.011
- Ульянова Я.С., Капустин Д.В., Краснова Е.И., Проворова В.В., Хохлова Н.И. Оценка эффективности лечения больных острой ВИЧ-инфекцией с использованием в схеме антиретровирусной терапии элсульфавирина Лечащий врач 2021; 6: 52–55. doi: 10.51793/OS.2021.24.6.011 / Ulianova IA. S., Kapustin D.V., Krasnova E.I., Provorova V.V., KHokhlova N.I. Evaluation of the effectiveness of treatment of patients with acute HIV infection using elsulfavirin in the antiretroviral therapy regimen. Attending doctor 2021; 6: 52–55. doi: 10.51793/OS.2021.24.6.011 (in Russian).
- Гудилина Н.А., Сибиряков А.В., Механошина Н.В., Иванова Э.С., Ростова Н.Б., Файзрахманов Р.А. Использование кластерного анализа при разработке подходов по выбору и назначению схем лечения ВИЧ-инфицированным пациентам. Бюллетень сибирской медицины 2017; 3 (16): 52–60. doi: 10.20538/1682-0363-2017-3-52-60 / Gudilina N.A., Sibiriakov A.V., Mekhanoshina N.V., Ivanova E.S., Rostova N.B., Faizrakhmanov R.A. The use of cluster analysis in developing approaches to selecting and prescribing treatment regimens for HIV-infected patients. Bulletin of Siberian Medicine 2017; 3 (16): 52–60. doi: 10.20538/1682-0363-2017-3-52-60 (in Russian).
- Гудилина Н.А., Иванова Э.С., Ростова Н.Б. Рациональная антиретровирусная терапия ВИЧ-инфицированных: мнение медицинских специалистов. Проблемы гигиены, здравоохранения и истории медицины 2018; 26: 411–414. doi: 10.32687/0869-866X-2018-26-6-411-414 / Gudilina N.A., Ivanova E.S., Rostova N.B. Rational antiretroviral therapy for HIV-infected people: the opinion of medical specialists. Problems of hygiene, health care and history of medicine 2018; 26: 411–414. doi: 10.32687/0869-866X-2018-26-6-411-414 (in Russian).
Supplementary files
